CancerNCT07816614
The Effect of Mandala Coloring on Quality of Life in Cancer Patients
A study testing Mandala Coloring in people with Cancer and Neoplasms (Cancer / Tumors), run by Emine TARLABELEN KARAYTUĞ at 1 site in Turkey (Türkiye).
Trial summary
This study aims to determine the effect of mandala coloring on the quality of life in cancer patients. Conducting a quasi-experimental design with a pretest-posttest control group, the study will involve a total of 76 cancer patients hospitalized in an oncology ward. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer, Neoplasms (Cancer / Tumors)
- What is being tested?
- Mandala Coloring
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 76 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- Oct 2026to Aug 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with cancer
- Aged 18 years and older
- Voluntarily willing to participate in the study
- Able to hold and use a pencil for coloring
Who cannot join
- Refusing to participate or withdraws consent before the study begins
- Unable to comply regularly with the scheduled mandala coloring program
- Incapable of using a pencil due to physical or cognitive impairments
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Aydın Adnan Menderes University Hospital
Aydin
TARLABELEN KARAYTUG, +90-531-384-2926, emine.karaytug@adu.edu.tr
About this study
This study aims to determine the effect of mandala coloring on the quality of life in cancer patients. Conducting a quasi-experimental design with a pretest-posttest control group, the study will involve a total of 76 cancer patients hospitalized in an oncology ward. Participants will be assigned to either the experimental (mandala) group or the control group. At the baseline, data will be collected face-to-face using a Patient Information Form and the EORTC QLQ-C30 Version 3.0 Quality of Life Scale. Patients in the experimental group will be provided with a mandala coloring book and colored pencils, and they will practice mandala coloring for 30 minutes, at least twice a week, over a 3-week period. The control group will receive routine clinical care with no intervention. After 3 weeks, the EORTC QLQ-C30 scale will be re-administered to both groups to evaluate and compare changes in their quality of life.
- Conditions
- Cancer, Neoplasms (Cancer / Tumors)
- Being tested
- Mandala Coloring
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mandala ColoringBehavioural
Also called Experimental Group
Patients in the experimental group will be provided with a mandala coloring book and a set of 12 colored pencils. They will be requested to practice mandala coloring in a quiet, distraction-free environment for 30 minutes, at least twice a week, for a total duration of 3 weeks. The intervention will be conducted in addition to routine clinical care.
| Study group | Role | What they receive |
|---|---|---|
| Mandala Coloring Intervention | Experimental | Patients in this group will be provided with a mandala coloring book and 12 colored pencils. They will practice mandala coloring for 30 minutes, at least twice a week, over a 3-week period in addition to routine clinical care. Receives: Behavioral: Mandala Coloring |
| Standard Care | No intervention | Patients in this group will receive only routine clinical care during the 3-week study period and will not perform any mandala coloring activity. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of Life Score via EORTC QLQ-C30
Quality of life will be evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Version 3.0. The questionnaire includes 30 items. All raw scores are linearly transformed into a standard scale ranging from 0 to 100. For the global health and functional scales, a higher score indicates a better quality of life. For the symptom scales, a higher score indicates a worse outcome.
Measured: Baseline and 3 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2026
- Study startOct 2026 (estimated)
- Primary completionJul 2027 (estimated)
- Study completionAug 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 76 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Emine TARLABELEN KARAYTUĞ
- Sponsor type
- University, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Responsible party
- Sponsor-investigator, Emine TARLABELEN KARAYTUĞ, Aydin Adnan Menderes University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07816614
- Sponsor's protocol ID
- 2026/557
- Status last verified
- Sep 2026
- First submitted
- 8 Sep 2026
- Last updated
- 15 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Mandala Coloring on Quality of Life in Cancer Patients
- ClinicalTrials.gov ID
- NCT07816614
- Acronym / sponsor ID
- 2026/557
- Conditions
- Cancer, Neoplasms (Cancer / Tumors)
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 76 participants (estimated)
- Lead sponsor
- Emine TARLABELEN KARAYTUĞUniversity, hospital or other
- Collaborators
- The Scientific and Technological Research Council of Turkey
- Study start
- Oct 2026 (estimated)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 11 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to determine the effect of mandala coloring on the quality of life in cancer patients. Conducting a quasi-experimental design with a pretest-posttest control group, the study will involve a total of 76 cancer patients hospitalized in an oncology ward. Participants will be assigned to either the experimental (mandala) group or the control group. At the baseline, data will be collected face-to-face using a Patient Information Form and the EORTC QLQ-C30 Version 3.0 Quality of Life Scale. Patients in the experimental group will be provided with a mandala coloring book and colored pencils, and they will practice mandala coloring for 30 minutes, at least twice a week, over a 3-week period. The control group will receive routine clinical care with no intervention. After 3 weeks, the EORTC QLQ-C30 scale will be re-administered to both groups to evaluate and compare changes in their quality of life.
Study design
- Primary purpose
- Supportive care
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mandala Coloring Intervention | Experimental | Behavioral: Mandala ColoringPatients in this group will be provided with a mandala coloring book and 12 colored pencils. They will practice mandala coloring for 30 minutes, at least twice a week, over a 3-week period in addition to routine clinical care. |
| Standard Care | No intervention | –Patients in this group will receive only routine clinical care during the 3-week study period and will not perform any mandala coloring activity. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosed with cancer
- Aged 18 years and older
- Voluntarily willing to participate in the study
- Able to hold and use a pencil for coloring
Key exclusion criteria (3 listed)
- Refusing to participate or withdraws consent before the study begins
- Unable to comply regularly with the scheduled mandala coloring program
- Incapable of using a pencil due to physical or cognitive impairments
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mandala ColoringAlso: Experimental GroupPatients in the experimental group will be provided with a mandala coloring book and a set of 12 colored pencils. They will be requested to practice mandala coloring in a quiet, distraction-free environment for 30 minutes, at least twice a week, for a total duration of 3 weeks. The intervention will be conducted in addition to routine clinical care. | Behavioural | Mandala Coloring Intervention |
Primary outcome
Quality of Life Score via EORTC QLQ-C30
Time frame: Baseline and 3 weeks
Quality of life will be evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Version 3.0. The questionnaire includes 30 items. All raw scores are linearly transformed into a standard scale ranging from 0 to 100. For the global health and functional scales, a higher score indicates a better quality of life. For the symptom scales, a higher score indicates a worse outcome.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2026.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Mandala Coloring in people with Cancer and Neoplasms (Cancer / Tumors), run by Emine TARLABELEN KARAYTUĞ at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Emine Tarlabelen Karaytug, Research Assistant, PhD (+90-531-384-2926, emine.karaytug@adu.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of Life Score via EORTC QLQ-C30 (time frame: Baseline and 3 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026.